Literature DB >> 16919470

BLyS receptor signatures resolve homeostatically independent compartments among naïve and antigen-experienced B cells.

Laura S Treml1, Jenni E Crowley, Michael P Cancro.   

Abstract

The BLyS family of receptors includes two cytokines, BLyS and APRIL; and three receptors, BR3, BCMA and TACI. Together, these regulate the size and composition of peripheral B cell pools. The multiplicity of ligand-receptor sets, in conjunction with differential receptor expression, alternative binding partners and disparate downstream signaling characteristics, affords the potential to establish independently regulated homeostatic niches among primary and antigen-experienced B cell subsets. Thus, BLyS signaling via BR3 is the dominant homeostatic regulator of primary B cell pools, whereas APRIL interactions with BCMA likely govern memory B cell populations. Short-lived antibody forming cell populations and their proliferating progenitors express a TACI-predominant signature. Further, within each niche, relative fitness to compete for available cytokine is determined by exogenous inputs via adaptive and innate receptor systems, affording intramural hierarchies that determine clonotype composition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16919470     DOI: 10.1016/j.smim.2006.07.001

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  17 in total

Review 1.  Homeostatic control of B lymphocyte subsets.

Authors:  Jenni E Crowley; Jean L Scholz; William J Quinn; Jason E Stadanlick; John F Treml; Laura S Treml; Yi Hao; Radhika Goenka; Patrick J O'Neill; Andrew H Matthews; Ronald F Parsons; Michael P Cancro
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 2.  Aberrant B-cell homeostasis in chronic GVHD.

Authors:  Stefanie Sarantopoulos; Jerome Ritz
Journal:  Blood       Date:  2015-02-02       Impact factor: 22.113

3.  Protective antiviral antibody responses in a mouse model of influenza virus infection require TACI.

Authors:  Amaya I Wolf; Krystyna Mozdzanowska; William J Quinn; Michele Metzgar; Katie L Williams; Andrew J Caton; Eric Meffre; Richard J Bram; Loren D Erickson; David Allman; Michael P Cancro; Jan Erikson
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

Review 4.  B cells in chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Bruce R Blazar; Corey Cutler; Jerome Ritz
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-12       Impact factor: 5.742

Review 5.  Regulatory roles of the tumor necrosis factor receptor BCMA.

Authors:  Christine M Coquery; Loren D Erickson
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

6.  BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.

Authors:  Luis Sanchez-Perez; Bryan D Choi; Elizabeth A Reap; Elias J Sayour; Pamela Norberg; Robert J Schmittling; Gerald E Archer; James E Herndon; Duane A Mitchell; Amy B Heimberger; Darell D Bigner; John H Sampson
Journal:  Cancer Immunol Immunother       Date:  2013-04-17       Impact factor: 6.968

7.  Cell-autonomous role for NF-kappa B in immature bone marrow B cells.

Authors:  Estefania Claudio; Sun Saret; Hongshan Wang; Ulrich Siebenlist
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

8.  Signaling pathways for B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in human placenta.

Authors:  Daudi L Langat; David A Wheaton; Jeralyn Sue Platt; Travis Sifers; Joan S Hunt
Journal:  Am J Pathol       Date:  2008-04-10       Impact factor: 4.307

Review 9.  Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment.

Authors:  Jean L Scholz; Michael P Cancro
Journal:  Immunol Lett       Date:  2012-02-06       Impact factor: 3.685

Review 10.  The BLyS family: toward a molecular understanding of B cell homeostasis.

Authors:  John F Treml; Yi Hao; Jason E Stadanlick; Michael P Cancro
Journal:  Cell Biochem Biophys       Date:  2008-11-26       Impact factor: 2.194

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.